Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
Why now
Thesis: Non-dilutive capital de-risks small-cap biotech development
Catalyst to watch: Phase 3 trial data or further government funding
Main risk: Clinical failure would erase program value
Why it matters
Non-dilutive defense funding extends runway for a Phase 3 antibiotic program without shareholder dilution.
Details
Initial Phase 3-focused funding to support advancement of AP-SA02 in complicated Staphylococcus aureus bacteremia New commitment is incremental to previously announced DoW funding and expands total non-dilutive support for the AP-SA02 program to $32.4 million LOS ANGELES, Sept. 23, 2026...
Sources
- prnewswire · 2026-09-23 11:00 UTC